<?xml version="1.0" encoding="UTF-8"?>
<p id="Par57">The designed compounds were assessed for their drug-friendliness. The molecules passed the drug- friendliness assessment (ADME and physicochemical properties) as shown in Table 
 <xref rid="Tab10" ref-type="table">10</xref>, none of the designed compounds violated two rules out of the Lipinski rule of five; a famous benchmark utilized in invalidating the drug-likeness of a molecule (as stated in “
 <xref rid="Sec13" ref-type="sec">Molecular Docking Studies</xref>” section). The bioavailability radar of molecules 11, 13, and 17 are shown in Fig. 
 <xref rid="Fig7" ref-type="fig">7</xref>. The bioavailability radar gives a quick and easy summary of the pharmacokinetic properties of a compound. The pink area signifies the ideal ranges for each property (lipophilicity: XLOGP3 from −0.7 to +5.0, size: molecular weight from 150 to 500 g/mol, polarity: TPSA from 20 to 130 Å
 <sup>2</sup>, solubility: log S less than 6, saturation: the fraction of carbons in the sp
 <sup>3</sup> hybridization not higher than 0.25, and flexibility: less than 9 rotatable bonds) (Daina et al. 
 <xref ref-type="bibr" rid="CR8">2017</xref>).
</p>
